BlackRock’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

BlackRock’s Portfolio DALS Stock Details DALS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,500,000	Closed	-$15.4M	–	5615
2023 Q2	$15.4M	Hold	1,500,000	–	–	﹤0.01%	3193
2023 Q1	$15.2M	Hold	1,500,000	–	–	﹤0.01%	3101
2022 Q4	$14.8M	Sell	1,500,000 -530	-0%	-$5.22K	﹤0.01%	3188
2022 Q3	$14.6M	Sell	1,500,530 -530	-0%	-$5.15K	﹤0.01%	3213
2022 Q2	$14.5M	Hold	1,501,060	–	–	﹤0.01%	3279
2022 Q1	$14.6M	Hold	1,501,060	–	–	﹤0.01%	3369
2021 Q4	$14.7M	Buy	1,501,060 +1,060	+0.1%	+$10.4K	﹤0.01%	3450
2021 Q3	$14.7M	Buy	+1,500,000	New	+$14.8M	﹤0.01%	3480

BlackRock's DALS Position: Q3 2023 in Review

BlackRock sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q3 2023, closing a stake of 1,500,000 shares — an estimated $15.4M sold.

BlackRock first reported a position in DALS in Q3 2021 and held it in 8 quarters. The position peaked at $15.4M in Q2 2023. 0 funds tracked by Wall St. Rank hold DALS as of Q3 2023.

BlackRock reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
BlackRock sold 1,500,000 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q3 2023, an estimated $15.4M.
BlackRock first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q3 2021 and held it in 8 quarters.
BlackRock's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $15.4M in Q2 2023.
0 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q3 2023.

Based on BlackRock's 13F filing for Q3 2023, filed 13 Nov 2023.